Please login to the form below

Not currently logged in
Email:
Password:

isosorbide mononitrate

This page shows the latest isosorbide mononitrate news and features for those working in and with pharma, biotech and healthcare.

AZ adds gout drug Zurampic to asset sale

AZ adds gout drug Zurampic to asset sale

Last month, AZ sold European rights to its opioid-induced constipation treatment Moventig (naloxegol) to ProStrakan and transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur (isosorbide mononitrate) -

Latest news

  • AZ offloads more products in slimming drive AZ offloads more products in slimming drive

    Meanwhile, earlier this week AZ also transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur (isosorbide mononitrate) - to China Medical System Holdings in a $500m deal.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2016 Deal Watch February 2016

    First launched in Europe in 1985, Imdur (isosorbide mononitrate) is an anti-angina drug in an oral extended release formulation with global sales outside the US of $57m in 2015.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics